Poly Medicure Limited

NSEI:POLYMED Rapporto sulle azioni

Cap. di mercato: ₹236.2b

Poly Medicure Gestione

Gestione criteri di controllo 2/4

Poly Medicure Il CEO è Himanshu Baid, nominato in Sep1995, e ha un mandato di 29.33 anni. la retribuzione annua totale è ₹ 171.78M, composta da 33.6% di stipendio e 66.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 11.59% delle azioni della società, per un valore di ₹ 27.38B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.6 anni e 6.7 anni.

Informazioni chiave

Himanshu Baid

Amministratore delegato

₹171.8m

Compenso totale

Percentuale dello stipendio del CEO33.6%
Mandato del CEO29.3yrs
Proprietà del CEO11.6%
Durata media del management6.6yrs
Durata media del Consiglio di amministrazione6.7yrs

Aggiornamenti recenti sulla gestione

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Recent updates

Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Jan 28
Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02
Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14
Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06
After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14
Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11
Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25
Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12
Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23
Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15
Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24
Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08
Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16
Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02
Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16
Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08
Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07
A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23
Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04
There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 12
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Oct 14
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Himanshu Baid rispetto agli utili di Poly Medicure?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹172m₹58m

₹3b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹130m₹55m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹1b

Jun 30 2022n/an/a

₹1b

Mar 31 2022₹107m₹49m

₹1b

Dec 31 2021n/an/a

₹1b

Sep 30 2021n/an/a

₹1b

Jun 30 2021n/an/a

₹1b

Mar 31 2021₹92m₹44m

₹1b

Dec 31 2020n/an/a

₹1b

Sep 30 2020n/an/a

₹1b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹62m₹35m

₹959m

Dec 31 2019n/an/a

₹947m

Sep 30 2019n/an/a

₹858m

Jun 30 2019n/an/a

₹719m

Mar 31 2019₹44m₹14m

₹654m

Mar 31 2018₹41m₹14m

₹706m

Compensazione vs Mercato: La retribuzione totale di Himanshu ($USD 1.98M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 572.63K ).

Compensazione vs guadagni: La retribuzione di Himanshu è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Himanshu Baid (56 yo)

29.3yrs

Mandato

₹171,781,000

Compensazione

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Himanshu Baid
CEO, MD & Director29.3yrs₹171.78m11.59%
₹ 27.4b
Jugal Baid
Founder & Non Executive Directorno data₹1.43m2.25%
₹ 5.3b
Naresh Vijayvergiya
Chief Financial Officer3.5yrs₹11.21mNessun dato
Avinash Chandra
Company Secretary & Compliance Officer9.7yrs₹1.88mNessun dato
Rishi Baid
Joint MD & Executive Directorno data₹166.82m12.33%
₹ 29.1b
Vishal Baid
President of Corporate Sales & Marketing2.8yrs₹18.39m1.66%
₹ 3.9b
P. Rastogi
Assistant Vice President of Finance & Accountsno dataNessun datoNessun dato
Hemant Bhalla
Senior Vice President of Domestic Sales & Marketingno data₹5.79mNessun dato
Pankaj Gupta
President of R&Dno data₹5.61mNessun dato
Manish Sardana
President of Sales & Marketing - Indiano data₹8.61mNessun dato

6.6yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di POLYMED è esperto e expertise (durata media dell'incarico 6.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Himanshu Baid
CEO, MD & Director29.8yrs₹171.78m11.59%
₹ 27.4b
Jugal Baid
Founder & Non Executive Director29.8yrs₹1.43m2.25%
₹ 5.3b
Rishi Baid
Joint MD & Executive Director29.8yrs₹166.82m12.33%
₹ 29.1b
Vimal Bhandari
Non-Executive Independent Directorless than a yearNessun datoNessun dato
Amit Khosla
Non-Executive Independent Director4.6yrs₹1.60mNessun dato
Vishal Gupta
Independent Directorno dataNessun datoNessun dato
Devendra Mehta
Non-Executive Independent Chairman19.7yrs₹1.63mNessun dato
Mukulika Baid
Non-Executive Director10.5yrs₹1.43m3.02%
₹ 7.1b
Sonal Mattoo
Non-Executive Independent Director4.4yrs₹1.45mNessun dato
Alessandro Balboni
Non-Executive Non Independent Director6.7yrs₹29.90mNessun dato
Ambrish Mithal
Independent Director2.8yrs₹1.45mNessun dato

6.7yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di POLYMED sono considerati esperti (durata media dell'incarico 6.7 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/01/31 10:07
Prezzo dell'azione a fine giornata2025/01/31 00:00
Guadagni2024/09/30
Guadagni annuali2024/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Poly Medicure Limited è coperta da 11 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Nitin BhasinAmbit Capital
Karan KhannaAmbit Capital
Sunita VaidyanathanBrics Securities Limited